Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.69 |
| ▸ | EGFR | P00533 | 9/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | RET | P07949 | 2/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | JAK3 | P52333 | 1/20 | 0.68 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.68 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.68 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.68 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.68 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 3/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25682990 | 0.84 | KDR (0.78) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL4760331 | 0.84 | PDGFRB (0.63) | KDREGFRPDGFRBFLT4RET | |
| SCHEMBL22164809 | 0.83 | EGFR (0.71) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL18158179 | 0.83 | EGFR (0.79) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL22300265 | 0.83 | EGFR (0.71) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL6689322 | 0.83 | PIK3CD (0.69) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL5865180 | 0.83 | EGFR (0.74) | KDREGFRRETGAKRIPK2 | |
| SCHEMBL22299657 | 0.83 | EGFR (0.67) | KDREGFRRETGAKRIPK2 | |
| Hydrochloric Acid SCHEMBL8811415 | 0.82 | EGFR (0.79) | KDREGFRRETGAKRIPK2 | |
| Hydrochloric Acid SCHEMBL8810155 | 0.82 | EGFR (0.79) | KDREGFRRETGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-7413727-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2008-08-19 | — | — | US | disclosed |
| EP-1442751-B1 | Diagnostic imaging technique | GE HEALTHCARE AS (NO) | 2007-06-20 | — | — | EP | disclosed |
| EP-1442751-A1 | Method of imaging | Amersham Health AS (NO) | 2004-08-04 | — | — | EP | disclosed |
| EP-0977600-B1 | CONTRAST AGENTS TARGETTING RECEPTORS ASSOCIATED WITH ANGIOGENESIS | AMERSHAM HEALTH AS (NO) | 2004-06-30 | — | — | EP | disclosed |
| US-20040009122-A1 | Contrast agents | AMERSHAM HEALTH AS (NO) | 2004-01-15 | — | — | US | disclosed |
| US-6610269-B1 | Disease state imaged using a targeted contrast agent of the formula V-L-R, where V is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker, R is a macromolecular or particulate label | AMERSHAM HEALTH AS (NO) | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | KDR 2584/4885EGFR 2429/4885PDGFRB 488/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | KDR 2584/4885EGFR 2429/4885PDGFRB 488/4885 |
| US-20040009122-A1 | Contrast agents | FLT1, FLT4, KDR | KDR 3/4885EGFR 54/4885PDGFRB 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.